The logical party to purchase a company like GAA is API.
API have no manufacturing margin to leverage in their dealings with pharmacy, unlike Sigma or Symbion. API is losing market share because of this.
The new API CEO is Stephen Roche (ex Faulding). The Faulding strategy was to "bundle" up tFaulding manufactured product to pharmacists. This has a hige profit impact as manufacturing margins can be 30-70%, whereas API only access a delivery fee at the moment. Stephen Roche will understand the importance of having a manufacturing business to improve the API margins.
GAA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
